Externalities from Medical Innovation: Evidence from Organ Transplantation

Kevin Callison, Michael E. Darden and Keith F. Teltser

Journal of Political Economy Microeconomics, 2025, vol. 3, issue 4, 763 - 797

Abstract: We evaluate the introduction of direct-acting antiviral (DAA) therapy for hepatitis C (HCV) on liver transplant allocation in the United States. We hypothesize that DAAs obviate the need for transplant for some HCV-positive patients, potentially benefiting HCV-negative registrants and inducing marginal HCV-negative patients to register. We find that DAA availability resulted in an additional 5,682 liver transplants to HCV-negative liver disease patients between 2014 and 2019, generating a positive externality of $7.52 billion. Furthermore, we show a 37% average annual increase in HCV-negative waiting list registrations. Without this behavioral response, DAA therapies would have eliminated the liver transplant waiting list.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://dx.doi.org/10.1086/733774 (application/pdf)
http://dx.doi.org/10.1086/733774 (text/html)
Access to the online full text or PDF requires a subscription.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ucp:jpemic:doi:10.1086/733774

Access Statistics for this article

More articles in Journal of Political Economy Microeconomics from University of Chicago Press
Bibliographic data for series maintained by Journals Division ().